PRODUCT DETAILS VIEW ALL PRODUCTS

Olmat AM Tablets (Olmesartan+ Amlodipine )

  • Each tablet contains Olmesartan 20mg / 40mg + Amlodipine 5mg.
  • Olmesartan 20mg + Amlodipine 5mg: For the treatment of mild to moderate hypertension. Olmesartan 40mg + Amlodipine 5mg: 1. For the treatment of hypertension alone or with other antihypertensive agents 2. To use as initial therapy in patients who are likely to need multiple antihypertensive agents to achieve their blood pressure goals.
  • Olmesartan is a selective AT1 subtype angiotensin II receptor antagonist. Angiotensin II is the principal pressor agent of the renin-angiotensin system, which leads to vasoconstriction, stimulation of synthesis and release of aldosterone, cardiac stimulation and renal reabsorption of sodium. Olmesartan blocks the vasoconstrictor effects of angiotensin II by selectively blocking the binding of angiotensin II to the AT1 receptor in vascular smooth muscle.Amlodipine is a calcium ion influx inhibitor of the dihydropyridine group and inhibits the transmembrane influx of calcium ions into cardiac and vascular smooth muscle. The mechanism of the antihypertensive action of amlodipine is due to a direct relaxant effect on vascular smooth muscle, leading to reductions in peripheral vascular resistance and in blood pressure. Amlodipine is relatively vessel-selective, with a greater effect on vascular smooth muscle cells than on cardiac muscle cells.
  • One tablet once daily.
  • Contraindicated in patients with known hypersensitivity to any active ingredients or any other component of this product.
  • Hypotension in volume- or salt-depleted patients with treatment initiation may be anticipated. Start treatment under close supervision. Impaired renal function: changes in renal function may be anticipated in susceptible individual. Increased angina or myocardial infarction may occur upon dosage initiation or increase.
  • Fetal toxicity-Pregnancy Category D:When pregnancy is detected, discontinue as soon as possible.It is not known whether olmesartan is excreted in human milk. Because of the potential for adverse effects on the nursing infant, a decision should be made whether to discontinue nursing or discontinue the drug, taking into account the importance of the drug to the mother.The safety and effectiveness in pediatric patients have not been established.
  • Olmesartan used concomitantly with NSAIDs use may lead to increased risk of renal impairment and loss of antihypertensive effect.Amlodipine- Strong inhibitors of CYP3A4(e.g. ketoconazole, itraconazole, ritonavir) may increase the plasma concentrations of amlodipine to a greater extent. Amlodipine increases the exposure of cyclosporine and tacrolimus.
  • The most common adverse reactions areperipheral edema, headache, dizziness, nausea and abdominal pain.
  • Anti-Hypertensives